Biovail Company Description
Specialty pharmaceutical firm Biovail concentrates on making improved versions of existing drugs using its oral drug delivery technologies, such as extended release and oral disintegration formulations. Its Biovail Pharmaceuticals unit makes and sells extended release versions of GlaxoSmithKline's Wellbutrin (Wellbutrin XL) and Sanofi-Aventis' blood pressure medication Cardizem (Cardizem LA), as well as genital herpes treatment Zovirax. Biovail relies on partnerships with other drug firms to sell its drugs in the US. Through its Biovail Pharmaceuticals Canada unit, the company sells some drugs in Canada (including anti-hypertensive Tiazac and Depomed's diabetes therapy Glumetza) using its own sales force.
View the Comprehensive Company Description for Biovail
The Company Description provides a historical perspective of Biovail's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Biovail's evolution in the marketplace.
